ANI Pharmaceuticals Inc.
ANIP | NASDAQ
$77.08
-$1.77 (-2.24%)
Sep 22, 2026, 2:08 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 883.37M | 614.38M | 486.82M | 316.39M | 216.14M | 208.48M |
Cost of Revenue | 432.73M | 250.21M | 181.51M | 138.79M | 100.61M | 87.16M |
Gross Profit | 450.64M | 364.17M | 305.3M | 177.6M | 115.53M | 121.32M |
Operating Income | 81.23M | 584K | 46.97M | -35.28M | -39.79M | -16.02M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 95.79M | -22.21M | 19.87M | -62.67M | -56.06M | -25.96M |
Net Income | 78.34M | -18.52M | 18.78M | -47.9M | -42.6M | -22.55M |
Selling & General & Admin | 317.75M | 249.64M | 161.7M | 124.04M | 84.29M | 64.99M |
Research & Development | 51.66M | 44.58M | 34.29M | 22.32M | 11.37M | 16M |
Other Expenses | n/a | 69.37M | 62.35M | 66.52M | 59.66M | 56.35M |
Operating Expenses | 369.41M | 363.58M | 258.33M | 212.88M | 155.32M | 137.33M |
Interest Expense | 20.06M | 17.6M | 26.94M | 28.05M | 11.92M | 9.45M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 802.14M | 613.79M | 439.85M | 351.67M | 255.93M | 224.49M |
Income Tax Expense | 17.45M | -3.69M | 1.09M | -14.77M | -13.46M | -3.41M |
Shares Outstanding (Basic) | 20.05M | 19.32M | 18M | 16.26M | 12.6M | 11.96M |
Shares Outstanding (Diluted) | 21.23M | 19.32M | 18.19M | 16.26M | 12.6M | 11.96M |
EPS (Basic) | 3.50 | -1.04 | 0.95 | -3.05 | -3.40 | -1.88 |
EPS (Diluted) | 3.32 | -1.04 | 0.94 | -3.05 | -3.40 | -1.88 |
EBITDA | 207.27M | 63.12M | 106.6M | 25.04M | 3.12M | 28.13M |
EBIT | 115.85M | -4.61M | 46.81M | -34.61M | -44.14M | -16.51M |
Depreciation & Amortization | 91.42M | 67.73M | 59.79M | 59.65M | 47.25M | 44.64M |
Add to Watchlist
Select watchlists to add or remove ANIP